Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech In $1.6 Billion Transaction
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal hinges on approval by Beijing's antitrust czars.
You may also be interested in...
PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)
Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.
China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
BEIJING - China's Ministry of Commerce has ordered Pfizer and Wyeth to divest themselves of certain business operations here in order to gain government approval for their $68-billion merger
China Emerging As Big Winner In Pharma Outsourcing Rush To Asia - PwC
BEIJING - Asia's expanding wealth and markets for drugs, combined with a pool of scientific talent and strengthening protections for patents, are propelling pharmaceutical multinationals to step up operations in the region in drug manufacturing, research and clinical trials